This is a Phase 1 study to evaluate the PK profile of TXL oral formulations in healthy subjects

This is a Phase 1 study to evaluate the PK profile of different oral formulations of TXL following single dose administration in healthy subjects.

Inclusion Criteria:

• Age:18-55 Capable of giving written informed consent Capable of completing study requirements

Exclusion Criteria:

• History or medical condition which could impact patient safety History of drug or alcohol abuse within past 2 years Positive result for HIV, HBV, or HCV Participation in another clinical trial within the past 90 days